Compare HLP & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLP | KZIA |
|---|---|---|
| Founded | 2021 | 1994 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.2M | 186.7M |
| IPO Year | 2021 | 2002 |
| Metric | HLP | KZIA |
|---|---|---|
| Price | $2.47 | $9.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.36 |
| AVG Volume (30 Days) | 121.3K | ★ 286.0K |
| Earning Date | 10-20-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $51.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $4.86 |
| 52 Week High | $2.61 | $17.40 |
| Indicator | HLP | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 82.70 | 34.44 |
| Support Level | $0.78 | $9.01 |
| Resistance Level | N/A | $14.85 |
| Average True Range (ATR) | 0.17 | 0.67 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 90.24 | 11.58 |
Hongli Group Inc is an offshore holding company. Through its subsidiaries, it is engaged in the cold-rolled steel profile manufacturing in China. Its main business operation focuses on the design, production, deep processing, and sales of custom-made profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation industries. The group operates in a single segment, which manufactures and sells agricultural machinery cab assemblies, construction machinery cab assemblies, excavator cab assemblies, and special-shaped steel pipes. It generates the majority of its reveneue from PRC.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.